Monitoring of Dual-Energy X-ray Absorptiometry Measurement in Clinical Practice

Journal of Clinical Densitometry

Volumn 9, Issue 3, 2006, Pages 281-286

  El Maghraoui, Abdellah ^a   Achemlal, Lahsen ^a   Bezza, Ahmed ^a  

^a MILITARY HOSPITAL MOHAMMED V   (Morocco)

Author keywords

Bone mineral density; dual energy X ray absorptiometry; reproducibility

Indexed keywords

ARTICLE; BONE DENSITOMETRY; CALCULATION; CLINICAL PRACTICE; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DUAL ENERGY X RAY ABSORPTIOMETRY; FOLLOW UP; HUMAN; OSTEOPOROSIS; PATIENT MONITORING; PRIORITY JOURNAL; REPRODUCIBILITY; STEROID THERAPY; TREATMENT OUTCOME;

ABSORPTIOMETRY, PHOTON; ADULT; AGED; ANALYSIS OF VARIANCE; BONE DENSITY; CHILD; DENSITOMETRY, X-RAY; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; REPRODUCIBILITY OF RESULTS;

EID: 33747376980     PISSN: 10946950     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jocd.2006.03.014     Document Type: Article

References (33)

1. El Maghraoui A., Koumba B.A., Jroundi I., Achemlal L., Bezza A., and Tazi M.A. Epidemiology of hip fractures in 2002 in Rabat, Morocco. Osteoporos Int 16 (2005) 597-602
2. Bono C.M., and Einhorn T.A. Overview of osteoporosis: pathophysiology and determinants of bone strength. Eur Spine J 12 Suppl 2 (2003) S90-S96
3. Kanis J.A., Johnell O., Oden A., Jonsson B., De Laet C., and Dawson A. Risk of hip fracture according to the World Health Organization criteria for osteopenia and osteoporosis. Bone 27 (2000) 585-590
4. Yeap S.S., and Hosking D.J. Management of corticosteroid-induced osteoporosis. Rheumatology (Oxford) 41 (2002) 1088-1094
5. Maricic M., and Gluck O. Densitometry in glucocorticoid-induced osteoporosis. J Clin Densitom 7 (2004) 359-363
6. El Maghraoui A. Corticosteroid induced osteoporosis. Press Med 33 (2004) 1213-1217
7. Phillipov G., Seaborn C.J., and Phillips P.J. Reproducibility of DXA: potential impact on serial measurements and misclassification of osteoporosis. Osteoporos Int 12 (2001) 49-54
8. Nguyen T.V., Sambrook P.N., and Eisman J.A. Sources of variability in bone mineral density measurements: implications for study design and analysis of bone loss. J Bone Miner Res 12 (1997) 124-135
9. Lodder M.C., Lems W.F., Ader H.J., et al. Reproducibility of bone mineral density measurement in daily practice. Ann Rheum Dis 63 (2004) 285-289
10. Maggio D., McCloskey E.V., Camilli L., et al. Short-term reproducibility of proximal femur bone mineral density in the elderly. Calcif Tissue Int 63 (1998) 296-299
11. Ravaud P., Reny J.L., Giraudeau B., Porcher R., Dougados M., and Roux C. Individual smallest detectable difference in bone mineral density measurements. J Bone Miner Res 14 (1999) 1449-1456
12. Fuleihan G.E., Testa M.A., Angell J.E., Porrino N., and Leboff M.S. Reproducibility of DXA absorptiometry: a model for bone loss estimates. J Bone Miner Res 10 (1995) 1004-1014
13. Rozenberg S., Vandromme J., Neve J., et al. Precision and accuracy of in vivo bone mineral measurement in rats using dual-energy X-ray absorptiometry. Osteoporos Int 5 (1995) 47-53
14. Nguyen T.V., and Eisman J.A. Assessment of significant change in BMD: a new approach. J Bone Miner Res 15 (2000) 369-372
15. Gluer C.C. Monitoring skeletal changes by radiological techniques. J Bone Miner Res 14 (1999) 1952-1962
16. Bland J., and Altman D. Statistical methods for assessing agreement between methods of clinical measurement. Lancet i (1986) 307-310
17. El Maghraoui A., Do Santos Zounon A.A., Jroundi I., et al. Reproducibility of bone mineral density measurements using dual X-ray absorptiometry in daily clinical practice. Osteoporos Int 16 (2005) 1742-1748
18. Johnson S.L., Petkov V.I., Williams M.I., Via P.S., and Adler R.A. Improving osteoporosis management in patients with fractures. Osteoporos Int 16 (2005) 1079-1085
19. Kanis J.A., Devogelaer J.P., and Gennari C. Practical guide for the use of bone mineral measurements in the assessment of treatment of osteoporosis: a position paper of the European foundation for osteoporosis and bone disease. The Scientific Advisory Board and the Board of National Societies. Osteoporos Int 6 (1996) 256-261
20. El Maghraoui A., Borderie D., Edouard R., Roux C., and Dougados M. Osteoporosis, body composition and bone turnover in ankylosing spondylitis. J Rheumatol 26 (1999) 2205-2209
21. Maillefert J.F., Aho L.S., El Maghraoui A., Dougados M., and Roux C. Changes in bone density in patients with ankylosing spondylitis: a two-year follow-up study. Osteoporos Int 12 (2001) 605-609
22. El Maghraoui A. Osteoporosis and ankylosing spondyltis. Joint Bone Spine 71 (2004) 573-578
23. Eastell R. Assessment of bone density and bone loss. Osteoporos Int 6 Suppl (1996) 3-5
24. Glüer C.C., Blake G., Lu Y., Blunt B.A., Jergas M., and Genank H.K. Accurate assessment of precision errors: how to measure the reproducibility of bone densitometry techniques. Osteoporos Int 5 (1995) 262-270
25. Li Z., Meredith M.P., and Hoseyni M.S. A method to assess the proportion of treatment effect explained by a surrogate end-point. Statist Med 20 (2001) 3175-3188
26. Cummings S.R., Karpf D.B., Harris F., et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 112 (2002) 281-289
27. Sarkar S., Mitlak B.H., Wong M., Stock J.L., Black D.M., and Harper K.D. Relationship between bone mineral density and incident vertebral fracture risk raloxifene therapy. J Bone Miner Res 17 (2002) 1-10
28. Wasnich R.D., and Miller P. Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 85 (2000) 231-236
29. Hochberg M.C., Greenspan S., Wasnich R.D., Miller P., Thompson D.E., and Ross P.D. Changes in bone density and turnover explain the reductions in incidence of non-vertebral fractures that occur during treatement with antiresorptive agents. J Clin Endocrinol Metab 87 (2002) 1586-1592
30. Watts N., Geusens P., Barton I.P., and Felsenberg D. Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD. J Bone Miner Res 20 (2005) 2097-2104
31. Hochberg M.C., Ross P.D., Black D., et al. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Arthr Rheum 42 (1999) 1246-1254
32. Roux C., Garnero P., Thomas T., Sabatier J.P., Orcel P., Audran M., and Comité Scientifique du GRIO. Recommendations for monitoring antiresorptive therapies in postmenopausal osteoporosis. Joint Bone Spine 72 (2005) 26-31
33. Blake G.M., and Fogelman I. Dual energy x-ray absorptiometry and its clinical applications. Semin Musculoskelet Radiol 6 (2002) 207-218